EICHORPublic-registry site landscape for NCT07752784, “Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.”, a Alzheimer's Disease study sponsored by JYAMS PET Research & Development Limited. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07752784 (registry record) |
| Study title | Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD. |
| Official title | A Clinicopathological Study to Evaluate the Concordance Between [18F]-APN-1607 Injection PET Imaging and Post-mortem Brain Tau Protein Pathological Changes in Cognitively Normal (HV) Subjects and Patients With AD-derived Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) Dementia. |
| Sponsor | JYAMS PET Research & Development Limited |
| Condition(s) | Alzheimer's Disease |
| Phase | PHASE3 |
| Listed sites | 1 |
| Intervention(s) | [18F]-APN-1607 |
| Site countries | China |
At Beijing Tiantan Hospital, Capital Medical University — one of the facilities listed on this trial — 1 other study is actively recruiting Alzheimer's Disease patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07752784.
Eichor generates a preliminary site-risk snapshot for NCT07752784 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
